We have located links that may give you full text access.
6B.09: EFFECT OF CANNABINOID RECEPTOR ACTIVATION ON ABERRANT MITOCHONDRIAL BIOENERGETICS IN HYPERTROPHIED CARDIAC MYOCYTES.
Journal of Hypertension 2015 June
OBJECTIVE: We recently reported that activation of endocannabinoid receptors attenuates cardiac myocyte hypertrophy. Mitochondrial dysfunction has emerged as a critical determinant of aberrant myocyte energy production in cardiac hypertrophy. Thus, we determined endocannabinoid influence on mitochondrial function in the hypertrophied cardiac myocyte.
DESIGN AND METHOD: The experimental paradigm of hypertrophy in this study was neonatal rat cardiac myocytes treated with endothelin-1 (ET1; 0.1 μM). Ligand activation of cannabinoid receptors was achieved using CB13 (1 μM), a peripherally-restricted dual agonist of cannabinoid receptor subtypes CB1 and CB2. Changes in mitochondrial membrane potential (δψm) were assessed by fluorescence microscopy using the potential sensitive dye, JC-1. Biochemical modulators of mitochondrial function (i.e. peroxisome proliferator-activated receptor-γ coactivator 1α [PGC-1α - a driver of mitochondrial biogenesis], carnitine palmitoyl transferase 1β [CPT-1β - facilitator of fatty acid uptake], and AMP-activated protein kinase [AMPK - energy sensor]) were assessed by real-time PCR and western blotting. The Seahorse Bioscience XF24 Analyzer was used to measure fatty acid oxidation-related bioenergetics parameters.
RESULTS: ET1 caused mitochondrial aberrations which included membrane depolarization (δψm 80 ± 5% vs. control; p < 0.05), reduced PGC-1α (59 ± 7% vs. control; p < 0.01) and CPT-1β (81 ± 5% vs. control; p < 0.05) expression, as well as depressed palmitate-dependent respiration (basal/maximal/reserved respiration respectively: 81 ± 5%, 78 ± 4%, 74 ± 5% vs. control; p < 0.05), coupling efficiency (83 ± 6% vs. control; p < 0.05), and respiratory control ratio (79 ± 5% vs. control; p < 0.01). CB13 treatment restored all mitochondrial parameters to normal. Incidentally, CB13 activated AMPK via phosphorylation at Thr172 (354 ± 58% vs. control; p < 0.01), and the ability of CB13 to improve mitochondrial membrane potential and PGC-1α was abolished by compound C (a chemical inhibitor of AMPK) or shRNA knockdown of AMPK. These data suggest that AMPK contributes to the mitochondrial protective effects of CB13.
CONCLUSIONS: The cardioprotective actions of liganded cannabinoid receptors extend to the mitochondrial level. Therefore, a cannabinoid-based treatment for cardiac disease remains a potential therapeutic strategy that warrants further study.
DESIGN AND METHOD: The experimental paradigm of hypertrophy in this study was neonatal rat cardiac myocytes treated with endothelin-1 (ET1; 0.1 μM). Ligand activation of cannabinoid receptors was achieved using CB13 (1 μM), a peripherally-restricted dual agonist of cannabinoid receptor subtypes CB1 and CB2. Changes in mitochondrial membrane potential (δψm) were assessed by fluorescence microscopy using the potential sensitive dye, JC-1. Biochemical modulators of mitochondrial function (i.e. peroxisome proliferator-activated receptor-γ coactivator 1α [PGC-1α - a driver of mitochondrial biogenesis], carnitine palmitoyl transferase 1β [CPT-1β - facilitator of fatty acid uptake], and AMP-activated protein kinase [AMPK - energy sensor]) were assessed by real-time PCR and western blotting. The Seahorse Bioscience XF24 Analyzer was used to measure fatty acid oxidation-related bioenergetics parameters.
RESULTS: ET1 caused mitochondrial aberrations which included membrane depolarization (δψm 80 ± 5% vs. control; p < 0.05), reduced PGC-1α (59 ± 7% vs. control; p < 0.01) and CPT-1β (81 ± 5% vs. control; p < 0.05) expression, as well as depressed palmitate-dependent respiration (basal/maximal/reserved respiration respectively: 81 ± 5%, 78 ± 4%, 74 ± 5% vs. control; p < 0.05), coupling efficiency (83 ± 6% vs. control; p < 0.05), and respiratory control ratio (79 ± 5% vs. control; p < 0.01). CB13 treatment restored all mitochondrial parameters to normal. Incidentally, CB13 activated AMPK via phosphorylation at Thr172 (354 ± 58% vs. control; p < 0.01), and the ability of CB13 to improve mitochondrial membrane potential and PGC-1α was abolished by compound C (a chemical inhibitor of AMPK) or shRNA knockdown of AMPK. These data suggest that AMPK contributes to the mitochondrial protective effects of CB13.
CONCLUSIONS: The cardioprotective actions of liganded cannabinoid receptors extend to the mitochondrial level. Therefore, a cannabinoid-based treatment for cardiac disease remains a potential therapeutic strategy that warrants further study.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app